Validation of a Novel Modified Aptamer-Based Array Proteomic Platform in Patients with End-Stage Renal Disease

End stage renal disease (ESRD) is characterized by complex metabolic abnormalities, yet the clinical relevance of specific biomarkers remains unclear. The development of multiplex diagnostic platforms is creating opportunities to develop novel diagnostic and therapeutic approaches. SOMAscan is an in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diagnostics (Basel) Jg. 8; H. 4; S. 71
Hauptverfasser: Han, Zhongji, Xiao, Zhousheng, Kalantar-Zadeh, Kamyar, Moradi, Hamid, Shafi, Tariq, Waikar, Sushrut S., Quarles, L. Darryl, Yu, Zhi, Tin, Adrienne, Coresh, Josef, Kovesdy, Csaba P.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Switzerland MDPI AG 08.10.2018
MDPI
Schlagworte:
biomarker
Biomarkers
Calibration
end-stage renal disease
Enzymes
Hemodialysis
Hybridization
Kidney diseases
Metabolism
Morbidity
Mortality
Plasma
Population
Proteins
Proteomics
Quality control
Reagents
Signal transduction
SOMAscan
validation
United States > US
SOMAscan
biomarker
end-stage renal disease
validation
ISSN:2075-4418, 2075-4418
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:End stage renal disease (ESRD) is characterized by complex metabolic abnormalities, yet the clinical relevance of specific biomarkers remains unclear. The development of multiplex diagnostic platforms is creating opportunities to develop novel diagnostic and therapeutic approaches. SOMAscan is an innovative multiplex proteomic platform which can measure >1300 proteins. In the present study, we performed SOMAscan analysis of plasma samples and validated the measurements by comparison with selected biomarkers. We compared concentrations of SOMAscan-measured prostate specific antigen (PSA) between males and females, and validated SOMAscan concentrations of fibroblast growth factor 23 (FGF23), FGF receptor 1 (FGFR1), and FGFR4 using Enzyme-Linked immunosorbent assay (ELISA). The median (25th and 75th percentile) SOMAscan PSA level in males and females was 4304.7 (1815.4 to 7259.5) and 547.8 (521.8 to 993.4) relative fluorescence units (p = 0.002), respectively, suggesting biological plausibility. Pearson correlation between SOMAscan and ELISA was high for FGF23 (R = 0.95, p < 0.001) and FGFR4 (R = 0.69, p < 0.001), indicating significant positive correlation, while a weak correlation was found for FGFR1 (R = 0.13, p = 0.16). In conclusion, there is a good to near-perfect correlation between SOMAscan and standard immunoassays for FGF23 and FGFR4, but not for FGFR1. This technology may be useful to simultaneously measure a large number of plasma proteins in ESRD, and identify clinically important prognostic markers to predict outcomes.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2075-4418
2075-4418
DOI:10.3390/diagnostics8040071